Stock Market Reviews

Read and share opinions on IBIO (iBio, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• iBio, Inc. (IBIO) Reports Q1 Loss
  Nov 12, 2025
• iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
  Nov 12, 2025
• iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
  Oct 30, 2025
• iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
  Oct 23, 2025
• iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
  Oct 21, 2025
• iBio Full Year 2025 Earnings: US$1.75 loss per share (vs US$4.03 loss in FY 2024)
  Sep 6, 2025
• iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
  Sep 5, 2025
• iBio Announces Closing of $50 Million Public Offering
  Aug 25, 2025
• iBio Announces Pricing of $50 Million Public Offering
  Aug 19, 2025
• iBio Announces Proposed Public Offering
  Aug 18, 2025
• iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
  Jun 24, 2025
• iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
  Jun 23, 2025
• iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
  Jun 16, 2025
• Insider Buyers At iBio Likely Disappointed With 23% Slide
  May 11, 2025
• iBio Reports Fiscal Third Quarter 2025 Financial Results
  May 2, 2025
• iBio Raises $6.2 Million Through Warrant Inducement Transaction
  Apr 29, 2025
• iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
  Apr 22, 2025
• iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
  Apr 7, 2025
• iBio to Begin Trading on the Nasdaq Stock Exchange
  Feb 19, 2025